Abstract
Objectives While pediatric population has largely remained free of severe COVID-19, in some cases SARS-CoV-2 infection has been associated with complications like Multiple Inflammatory Syndrome in children (MIS-C). We mention another unique presentation subsequent to asymptomatic infection of SARS-CoV-2, a transient form of hepatitis designated as COVID-19 Associated Hepatitis in Children (CAH-C). The clinical presentations, temporal association and viral parameters of the cases of CAH-C contrasting to MIS-C hepatitis are presented here.
Design As a retrospective and follow-up observational study we reviewed all pediatric patients presenting to our hospital with acute hepatitis. Increased number of such cases of hepatitis during the second wave of SARS CoV-2 infections, where children or adolescents developing sudden onset acute hepatitis with temporal relation to SARS-CoV-2 infection and without prior liver disease or familiar etiology of acute hepatitis are described.
Results Among 47 pediatric patients presented with hepatitis, 37 patients had features of CAH-C, they had symptoms of hepatitis only, with majority having unelevated inflammatory markers and uneventful recovery following supportive treatment. Whereas remaining 10 MIS-C hepatitis had protracted illness, multiple system involvement, required admission to critical care, and had mortality of 30% (3/10).
Conclusion With the emergence of newer variants of concern (VOC) including the Delta variant which has now spread to more than 60 countries and was responsible for the massive wave of COVID-19 across India, with changing presentations, CAH-C might be one of them. Such new entities need to be identified and differentiated from other emerging syndromes in children for a timely and appropriate intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external grant has been used for the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the IRB and the institutional human ethics committee, Bundelkhand Medical College, Sagar registration number ECR/1252/Inst/MP/2019. The follow-up and analysis work was performed after the ethical approval was granted by the institutional human ethics committee of our institute. Wide reference letter IEC/BMC/80/21.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant support: NA
This revised version has a shortened abstract to comply with word limitations in reputed journals. Some parts of Introduction and discussion have been rewritten and done with unnecessary repetitions to present a more clear picture about the study participants based on the reviews and queries of readers. The number of cases in both CAH-C and MIS-C have increased with inclusion of cases up-to July 2021. Statistical analysis has also incorporated all these cases and with improvements to it. Some redundant sentences have been removed from where they reappeared.
Data Availability
All data related to the manuscript is available with the author.
https://main.icmr.nic.in/sites/default/files/press_realease_files/ICMR_PR_IgG_Elisa_30052020.pdf
